Cancer

Buck Institute and Sens.ai Collaborate to Study Brain Aging

New Longevity Tech Collaboration Will Research and Develop First-Ever Biological Clock for the Brain WHISTLER, BC, June 6, 2024 /PRNewswire/…

4 days ago

Northern Arizona Healthcare Selects Noetic Consultants as Brand Partner

Comprehensive brand and reputation analysis will center around listening FLAGSTAFF, Ariz., June 6, 2024 /PRNewswire/ -- Northern Arizona Healthcare (NAH),…

4 days ago

Health Catalyst Acquires Oncology-Focused Health Technology Company Carevive

SALT LAKE CITY, June 6, 2024 /PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and…

4 days ago

How Merck Scientists Are Driving Next-Generation Cancer Research

The company's scientists are accelerating research by looking to improve anti-tumor immune response, targeting specific cancer cells and helping inhibit…

4 days ago

Theralase(R) Successfully Destroys Lung Cancer

TORONTO, ON / ACCESSWIRE / June 6, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF) is a clinical…

4 days ago

Scientific Journal Reports Findings that Show LIXTE’s Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System

LB-100 Generates Neo-Antigens in Cancer Cells that are Presented to the Immune System by Disrupting the Process of RNA Splicing…

4 days ago

Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease

Company expects to lock database in June andremains on track to report key outcomes later in July. Pepinemab targets astrocyte…

4 days ago

Anthos Therapeutics Announces ~84% of Eligible Patients Have Transitioned to Abelacimab in the AZALEA-TIMI 71 Extension Study of Atrial Fibrillation Patients at a Moderate-to-High Risk of Stroke

75% of patients in the rivaroxaban arm voluntarily switched from the once-daily oral anticoagulant to once-monthly abelacimab Landmark AZALEA-TIMI 71 Study…

4 days ago

Defence’s AccuTOX Published in the Prestigious Journal of Translational Medicine Its Peer Study with Preclinical Data on AccuTOX as an Anti-Cancer Molecule

Vancouver, British Columbia--(Newsfile Corp. - June 6, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or…

4 days ago

Enspectra Health Receives FDA Breakthrough Device Designation for AI-powered Imaging Platform Targeting Skin Cancer

MOUNTAIN VIEW, Calif., June 5, 2024 /PRNewswire/ -- Enspectra Health, a health tech company, today announced that the U.S. Food…

5 days ago